In another retrospective analysis of 37 patients with unresectable stage III EGFR‐mutated NSCLC, PFS was not significantly different between patients who received durvalumab and those who received CRT alone (10.3 months vs. 6.9 months).26 This evidence concerns the gene EGFR and non-small cell lung carcinoma.